— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA —
— Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET —
– Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET – First and only approved option: YARTEMLEA ®...
Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart...
– Conference Call Today at 4:30 p.m. ET
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes. Omeros...
Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.
Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential.
In a report released today, Serge Belanger from Needham maintained a Hold rating on Omeros. The company’s shares opened today at $11.59.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...